Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203–15 (1988).

Castilla, E.E. et al. Thalidomide, a current teratogen in South America. Teratology 54, 273–7 (1996).

Stephens, T.D. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38, 229–39 (1988).

Wells, P.G. & Winn, L.M. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31, 1–40 (1996).

Parman, T., Chen, G. & Wells, P.G. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry and photochemical product analysis. J. Biol. Chem. 273, 25079–88 (1998).

Liu, L. & Wells, P.G. DNA oxidation as a potential molecular mechanism mediating drug- induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19, 639–48 (1995).

Arlen, R.R. & Wells, P.G. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: Validation with paraquat and t-butylhydroperoxide and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4, A608 (1990).

Arlen, R.R. & Wells, P.G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharm. Exp. Ther. 277, 1649–58 (1996).

Wells, P.G., Kim, P.M., Nicol, C.J., Parman, T. & Winn, L.M. in Handbook of Experimental Pharmacology Vol. 124, Part I, Ch. 17 (eds. Kavlock, R.J. & Daston, G.P.) 453 –518 (Springer-Verlag, Heidelberg, 1997).

Winn, L.M. & Wells, P.G. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22, 607– 21 (1997).

Kim, P.M. & Wells, P.G. Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharm. 49, 172–81 (1996).

Cheng, K.C., Cahill, D.S., Kasai, H., Nishimura, S. & Loeb, L.A. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—-T and A—-C substitutions. J. Biol. Chem. 267, 166–72 (1992).

Ashby, J. et al. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat. Res. 396, 45– 46 (1997).

Schumacher, H., Smith, R.L. & Williams, R.T. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338–351 (1965).

Gordon, G.B., Spielberg, S.P., Blake, D.A. & Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Nat. Acad. Sci. USA 78, 2545– 8 (1981).

Huang, P.H. & McBride, W.G. Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo [see comments]. Teratogen. Carcinogen. Mutagen. 17, 1–5 (1997).

Neubert, D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratogen. Carcinogen. Mutagen. 17, i– ii (1997).

Braun, A.G., Harding, F.A. & Weinreb, S.L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharm. 82, 175–9 (1986).

Hatfill, S.J., Fester, E.D., de Beer, D.P. & Bohm, L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15, 129–36 (1991).

Jonsson, N.A. Chemical structure and teratogenic properties 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharma. Suec. 9, 521– 42 (1972).

Wuest, H.M., Fox, R.R. & Crary, D.D. Relationship between teratogenicity and structure in the thalidomide field. Experientia 24, 993– 4 (1968).

Kitada, M. & Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal- specific expression. Drug Metab. Rev. 26, 305–23 (1994).

Pottenger, L.H. & Jefcoate, C.R. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 11, 321–7 (1990).

Yang, H.Y., Lee, Q.P., Rettie, A.E. & Juchau, M.R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46, 922– 8 (1994).

Winn, L.M. & Wells, P.G. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266–74 (1999).